Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavocept with Docetaxel and Cisplatin in Advanced NSCLC
NCT00077311Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2004
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dimesna in chemotherapy-induced peripheral neuropathy (CIPN) and cisplatin-induced nephrotoxicity (CIN) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Incidence and severity of peripheral neuropathy at 12 weeks, Feasibility of regimens (febrile neutropenia and treatment delays) at 12 weeks and 1 more. Started Aug 2004; status: completed.
02
Drugs
dimesna
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)cisplatin-induced nephrotoxicity (CIN)
Beyond the preview
Go deeper on NCT00077311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077311.